Objective: To identify the genetic cause of a complex syndrome characterized by autophagic vacuolar myopathy (AVM), hypertrophic cardiomyopathy, pigmentary retinal degeneration, and epilepsy.
Figure 1
Family pedigree and genetic investigations (A) Family pedigree and Sanger sequencing validation study of the c.494G.A mutation in the carrier mother (IV-1) and the 2 affected patients (V-1 and V-2). (B) T1-weighted brain MRI of V-1 performed at the age of 38 years showing mild cerebral and cerebellar atrophy. (C) Clustal Omega multiple alignment showing that glycine at position 165 (green highlighted) is conserved across very distant species and is part of a highly conserved small stretch of amino acids. (D) Schematic representation of CLN3 protein showing the relative position of the mutations in the second luminal loop of CLN3. The second luminal loop of CLN3 contains 12 pathogenic mutations, including 6 other missense mutations, suggesting that it is functionally or structurally important to CLN3 function. The transmembrane domains of CLN3 are shown as blue boxes and the cytosolic and lysosomal facing domains as lines. The mutations previously reported in the literature are shown in black. The novel p.Gly165Glu mutation reported here is shown in red.
Genetic analysis. Genome-wide, single nucleotide polymorphism genotyping was performed in the 2 affected individuals (V-1 and V-2) and the mother. Each individual was assayed on an Illumina chip (HumanOmniExpress-12v1_H; Illumina, Inc., San Diego, CA). Data were analyzed using the GenomeStudio 2010.3 Genotyping Module (Illumina) and BeadStudio suite.
Whole-exome sequencing was performed on individuals V-1 and V-2 on a HiSeq2000 next-generation sequencing platform (Illumina) and data processed through Novoalign and SAMtools 0.18.
Primers for PCR amplification of the exon containing the mutation are available upon request.
RESULTS
Clinical features. The patients (V-1, now aged 48 years, and V-2, aged 41 years) were born into a consanguineous family ( figure 1A ). There is no family history of neurologic disease. Both siblings presented at the age of 7 years with visual loss rapidly progressing to total blindness. A diagnosis of retinitis pigmentosa was made. They had normal psychomotor development and, after graduating from high school, started to work as switchboard operators. No other symptoms were reported until the age of 36 (V-1) and 29 (V-2), when they presented with generalized tonic-clonic seizures responsive to wide-spectrum antiepileptic drugs. Brain MRI showed the presence of mild cerebral and cerebellar vermian atrophy ( figure 1B) . At the same time, they were diagnosed with sick sinus syndrome and cardiac conduction defect and treated with pacemaker implantation and, later, implantable cardiac defibrillator. Cardiac echo scan showed the presence of concentric hypertrophic cardiomyopathy. Cardiac function progressively deteriorated over 5 years to cardiac failure (New York Heart Association class III). Both patients are now waiting for cardiac transplant. At the age of 42 (V-1) and 37 (V-2), neurologic examination was strictly normal apart from blindness. Neuropsychological examination was uneventful apart from mild impairment of verbal fluency and executive functions. Ophthalmologic fundus evaluation was uninformative because of bilateral lens opacity. EEG showed normal background activity and rare isolated diffuse spikes and sharp waves. Increased creatine kinase (up to 600 U/L) was detected in seizure-free periods. EMG showed the presence of mild myogenic features.
Muscle pathology. Muscle biopsy alterations were similar in both brothers. Light microscopy examination was suggestive of an AVM. The most common finding was the presence of vacuoles involving approximately 50% of fibers. Autophagic vacuoles showed a strong reaction for lysosomal acid phosphatase activity. Immunohistochemical analysis revealed a positive binding at vacuolar membrane level, using dystrophin and human leukocyte antigen class 1 (HLA1) antibodies (figure 2). There was also clear autofluorescence (data not shown).
Ultrastructural examination (figure 3) showed vacuoles containing free glycogen, lysosomal glycogen sacs, and frequent autophagic debris including myelinlike figures in several muscle fibers. There were also intermyofibrillar and subsarcolemmal accumulations of electron-dense material that in some cases were arranged to form structures similar to curvilinear bodies.
The ultrastructural examination of blood lymphocytes revealed cytoplasmic vacuolization characteristic of CLN3 disease. Electron microscopy did not show the presence of fingerprint profiles in either skeletal muscle or lymphocytes.
Genetic investigation. Mitochondrial DNA and LAMP2 genetic testing were normal. Whole-genome genotyping identified 3 shared homozygosity segments (2 regions on chromosome 16 of 5 and 9 Mb, respectively, and a region of 1 Mb on chromosome 13). Exome sequencing identified 62 homozygous variants in Because mutations in the latter are known to cause an autosomal recessive neurodegenerative disease that presents with visual failure, we further investigated the novel mutation in this gene. The mutation occurred in exon 7 of CLN3 (c.494G.A), causing a glycine to glutamic acid substitution at amino acid residue 165 (p.Gly165Glu) on the second luminal loop domain of CLN3 protein. 7 By Sanger sequencing, we confirmed the presence of the homozygous c.494G.A mutation in the siblings and in one allele of the mother ( figure 1A) . No other living relatives were available for genetic testing. The effect of p.Gly165Glu mutation on gene function was predicted to be "probably damaging" by Poly-Phen (PSIC [position-specific independent counts] score difference 12.89) and "damaging" by SIFT.
DISCUSSION Classic juvenile CLN3 disease is an autosomal recessive inherited progressive encephalopathy of childhood due to disruption of the function of CLN3. 8 The most common mutation is a 1-kb deletion that removes exons 7 and 8. 9 Our cases showed a very protracted disease course without motor deterioration and only slight cognitive impairment after 40 years of disease duration. Atypical phenotypes, including some less severe, have previously been reported in individuals who are compound heterozygotes for the 1-kb deletion and some homozygous mutations. 5, 9, 10 Multiple genetic evidences point to a pathogenic role of the novel CLN3 p.Gly165Glu mutation reported here, including in silico approaches, conservation of glycine residue at position 165 among very distant species ( figure 1C) , and previous identification of 6 other missense mutations in flanking regions ( figure 1D ). 5, 7 Of note, pathologic hallmarks of CLN3 disease, such as autofluorescent material (data not shown), electron-dense storage material resembling curvilinear bodies, and vacuolated lymphocytes were also present.
Although fingerprint profiles are reportedly difficult to demonstrate in muscle tissue of patients with CLN3 disease, 11 their absence at lymphocytes electron microscopy examination could represent a variant in our reported cases. Also, a modifier effect of SH2B1 and ASPHD1 mutations on the pathologic and clinical phenotype cannot be excluded in our patients.
Cardiac function impairment in our patients is consistent with recently recognized cardiac involvement at later stages of the disease in protracted cases of CLN3 disease. 12 Of note, muscle biopsy of both patients was characterized by the presence of autophagic vacuoles. The striking discrepancy between their normal skeletal muscle strength and the widespread vacuolar changes parallels recent experimental evidence of a possible protective role of autophagy in muscle in CLN3 disease. 13, 14 Although autophagic vacuoles did not show acetylcholinesterase activity on their membranes, as described in typical autophagic vacuoles with unique sarcolemmal features, the histologic features of the biopsies present striking similarities with other AVMs with autophagic vacuoles with unique sarcolemmal features, namely, dystrophin and HLA1-positive autophagic vacuoles. This finding highlights the importance of considering a protracted CLN3 disease and, if appropriate, performing CLN3 genetic testing in the diagnostic workup of individuals with AVM, particularly if there is visual impairment and cardiac muscle is involved.
